Resource Summary Report

Generated by ASWG on Aug 10, 2026

Mouse Anti-CD38 Monoclonal Antibody, PE-Cy7 Conjugated, Clone HB7

RRID:AB_399969
Type: Antibody

Proper Citation

BD Biosciences Cat# 335790, RRID:AB_399969

Antibody Information

URL: http://antibodyregistry.org/AB_399969

Proper Citation: BD Biosciences Cat# 335790, RRID:AB_399969

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: vendor suggested use: Flow Cytometry; FCM; Vendor suggested use: Flow Cytometry; FCM

Antibody Name: Mouse Anti-CD38 Monoclonal Antibody, PE-Cy7 Conjugated, Clone HB7

Description: This monoclonal targets CD38

Clone ID: Clone HB7

Antibody ID: AB_399969

Vendor: BD Biosciences

Catalog Number: 335790

Record Creation Time: 20250820T043249+0000

Record Last Update: 20250820T191558+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-CD38 Monoclonal Antibody, PE-Cy7 Conjugated, Clone HB7.

No alerts have been found for Mouse Anti-CD38 Monoclonal Antibody, PE-Cy7 Conjugated, Clone HB7.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Ediriwickrema A, et al. (2025) A single-cell framework identifies functionally and molecularly distinct multipotent progenitors in adult human hematopoiesis. Cell reports, 44(9), 116236.

Dhenni R, et al. (2025) Macrophages direct location-dependent recall of B cell memory to vaccination. Cell, 188(13), 3477.

Jakobsen NA, et al. (2024) Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell stem cell, 31(8), 1127.

Rivera M, et al. (2024) Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell reports, 43(2), 113704.

Ma K, et al. (2023) CEA cell adhesion molecule 5 enriches functional human hematopoietic stem cells capable of long-term multi-lineage engraftment. iScience, 26(12), 108561.

Crews LA, et al. (2023) Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell stem cell, 30(3), 250.

Friman V, et al. (2023) Defective peripheral B cell selection in common variable immune deficiency patients with autoimmune manifestations. Cell reports, 42(5), 112446.

van der Werf I, et al. (2023) Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. Cell reports. Medicine, 4(3), 100962.

Law H, et al. (2022) Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. iScience, 25(1), 103656.

Reilly A, et al. (2022) Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function. Cell stem cell, 29(4), 577.

Krivdova G, et al. (2022) Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML. Cell reports, 38(10), 110481.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell stem cell, 28(4), 623.

Takayama N, et al. (2021) The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. Cell stem cell, 28(3), 488.

Jiang Q, et al. (2021) Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell reports, 34(4), 108670.

Vora AA, et al. (2021) Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. STAR protocols, 2(2), 100565.

Caduff N, et al. (2021) KSHV infection drives poorly cytotoxic CD56-negative natural killer cell differentiation in vivo upon KSHV/EBV dual infection. Cell reports, 35(5), 109056.

García-Prat L, et al. (2021) TFEB-mediated endolysosomal activity controls human hematopoietic stem cell fate. Cell stem cell, 28(10), 1838.

Vora P, et al. (2020) The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell stem cell, 26(6), 832.

Salim SK, et al. (2020) Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis. STAR protocols, 1(3), 100124.

Shin JJ, et al. (2020) Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. Cell reports, 32(9), 108093.